Table 1 Changes from baseline to end of Week 12 in secondary endpoints in patients with PAH-CHD in PATENT-1 (observed values):

PVR (dyn·s·cm–5)

11

1312±763

-66±632

13

1130±664

-250±410

7

1047±564

-126±368

NT-proBNP (pg/mL)

12

1573±1775

-46±697

13

761±1172

-164±317a

7

1352±1350

-872±1147a

WHO FC (%)

12

II – 58%

Improved 8%

15

II – 67%

Improved 21%

8

II – 50%

Improved 29%

III – 42%

Stabilized 83%

III – 33%

Stabilized 79%

III – 50%

Stabilized 71%

Worsened 8%

Worsened 0%^a

Worsened 0%^a

Borg dyspnea score

12

4.3±2.7

-0.1±2.4

15

2.5±1.4

-0.3±1.3^b

8

3.2±1.6

-0.8±0.8^a

EQ-5D score

12

0.74±0.16

-0.05±0.22

15

0.78±0.15

0.03±0.18^a

8

0.74±0.08

+0.09±0.14^a

LPH score

12

40.4±20.0

-0.1±15.8

15

34.9±26.0

-8.0±15.9^a

8

40.0±15.3

-13.7±13.2^a